Solution Provides Single Platform for Data Capture, Processing and Reporting for Clinical Studies
Merge Healthcare Incorporated (Nasdaq:MRGE), a provider of clinical systems, announced that Worldwide Clinical Trials, Inc. has selected Merge's eClinical OS(TM) solution to accelerate study startup, streamline electronic data capture (EDC), and maximize operational efficiency across its Phase I-IV studies.
"We are always looking for ways to increase efficiency and improve study timelines," explained Graham Downing, Vice President of Global Data, Statistics and Technology at Worldwide Clinical Trials, Inc. "Adding a system to our solutions portfolio that would enable rapid study database set-up, efficiencies in data processing, and that incorporated status and metrics reporting was key."
"The implementation of eClinical OS at Worldwide Clinical Trials represents an opportunity to increase awarded studies," Downing continued. "The straight-forward interface and user experience allows studies to be built and deployed in a fraction of the time of other tools. With eClinical OS, we've seen a significant improvement in our study start-up timelines and processing efforts allowing us to pass on cost savings to our clients. This is a valuable further solution that we offer to our sponsor projects."
"Merge eClinical OS has the flexibility to support trials in all phases. Worldwide Clinical Trials initially selected eClinical OS as a cost-effective, easy-to-use system that would accelerate startup and streamline management of their clients' Phase I trials," said Justin Dearborn, President of Merge Healthcare. "They are now implementing eClinical OS for other phases and trials. We are pleased to have been selected as a provider for their global clinical trial needs, and look forward to working closely with them as they expand their use of eClinical OS."
Merge eClinical OS provides end-to-end study support through a single, easy-to-use interface so clients can manage and run studies more efficiently than ever before. It delivers built-in study templates, libraries and reports to help users create studies quickly and manage them effectively without technical assistance. Merge eClinical OS works for the largest and smallest of studies, has the flexibility to support trials in any phase, and captures any type of data, from any source, over any modality. It also has the scalability to grow if a trial increases in size, number or complexity.
Cautionary Notice Regarding Forward-Looking Statements
The matters discussed in this news release may include forward-looking statements, which could involve a number of risks and uncertainties. When used in this press release, the words "will," "believes," "intends," "anticipates," "expects" and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, such forward-looking statements. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.